Fate Therapeutics grants options to director Yuan Xu

Fate Therapeutics director Yuan Xu received a new stock option grant as board compensation.

Rhea-AI Filing Summary

Fate Therapeutics director Yuan Xu received a new stock option grant as board compensation. The award covers 87,900 shares of common stock at an exercise price of $2.06 per share and is held directly. Following this grant, Xu holds options on 87,900 underlying shares.

The option vests and becomes exercisable on the earlier of June 12, 2027 or the date of Fate Therapeutics’ 2027 annual stockholder meeting, as long as Xu continues serving on the board. This is a non-employee director equity grant under the company’s compensation policy, not an open-market purchase or sale.

Insights

Equity Compensation Analyst

Routine director option grant with no immediate cash transaction.

Director Yuan Xu was granted options over 87,900 shares of Fate Therapeutics common stock at an exercise price of $2.06. This comes from the company’s non-employee director compensation policy, indicating standard equity-based board pay rather than an opportunistic market trade.

The option vests on the earlier of June 12, 2027 or the 2027 annual meeting, contingent on continued board service. Because this is a compensation grant with no open-market buying or selling and represents a single award, the investment thesis impact is neutral.

Insider Trade Summary

Grant/Award: 87,900 shares

Grant/Award 1 txn

Insider Xu Yuan

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	87,900	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 87,900 contracts (Direct)

Footnotes (2)

1. F1. This transaction represents a grant of options pursuant to the terms of the Issuer's Amended and Restated Non-Employee Director Compensation Policy which provides for annual equity grants to the Issuer's non-employee directors on the date of the Issuer's Annual Meeting of Stockholders.
2. F2. The shares subject to this option shall vest and become exercisable on the earlier of (i) June 12, 2027 or (ii) the date of the Issuer's 2027 Annual Meeting of Stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors.

Key Figures

Option grant size: 87,900 shares Exercise price: $2.06 per share Options after transaction: 87,900 shares +2 more

5 metrics

Option grant size 87,900 shares Stock Option (Right to Buy) granted to director Yuan Xu

Exercise price $2.06 per share Conversion or exercise price for the stock option grant

Options after transaction 87,900 shares Total underlying shares following the reported option grant

Option expiration June 12, 2036 Expiration date of the stock option award

Vesting date trigger Earlier of June 12, 2027 or 2027 meeting Vesting contingent on continued board service

Key Terms

Stock Option (Right to Buy), Amended and Restated Non-Employee Director Compensation Policy, Annual Meeting of Stockholders, vest and become exercisable, +1 more

5 terms

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

Amended and Restated Non-Employee Director Compensation Policy financial

"provides for annual equity grants to the Issuer's non-employee directors"

Annual Meeting of Stockholders regulatory

"annual equity grants to the Issuer's non-employee directors on the date of the Issuer's Annual Meeting of Stockholders"

vest and become exercisable financial

"The shares subject to this option shall vest and become exercisable on the earlier of"

Reporting Person's continued service regulatory

"subject to the Reporting Person's continued service on the Issuer's Board of Directors"

FAQ

What did Fate Therapeutics (FATE) director Yuan Xu report in this Form 4?

Yuan Xu reported receiving a stock option grant for 87,900 shares of Fate Therapeutics common stock. The options were awarded under the company’s non-employee director compensation policy as equity-based board compensation, rather than as an open-market purchase of existing shares.

What is the exercise price of Yuan Xu’s new Fate Therapeutics stock options?

The exercise price of Yuan Xu’s new stock options is $2.06 per share. This means Xu can buy up to 87,900 Fate Therapeutics common shares at $2.06 each once the options vest and become exercisable, subject to continued board service conditions.

When do Yuan Xu’s Fate Therapeutics options vest and become exercisable?

The options vest on the earlier of June 12, 2027 or the date of Fate Therapeutics’ 2027 annual stockholder meeting. Vesting requires that Yuan Xu continue serving on the company’s board of directors through that vesting date under the grant’s terms.

How many Fate Therapeutics shares are underlying Yuan Xu’s new option grant?

The option grant covers 87,900 underlying shares of Fate Therapeutics common stock. After this transaction, the Form 4 shows total options held following the grant at 87,900 underlying shares, reflecting this single director compensation award reported in the filing.

Is Yuan Xu’s Form 4 transaction a market buy or sell of Fate Therapeutics stock?

No, the Form 4 reports a grant of options, not a market trade. The transaction code A indicates a grant or award acquisition, and the footnotes describe it as part of Fate Therapeutics’ non-employee director compensation policy rather than an open-market purchase or sale.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/15/2026 - 04:10 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Xu Yuan

(Last) (First) (Middle)

C/O FATE THERAPEUTICS, INC.

12278 SCRIPPS SUMMIT DRIVE

(Street)

SAN DIEGO CALIFORNIA 92131

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
FATE THERAPEUTICS INC [ FATE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/12/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$2.06	06/12/2026		A(1)		87,900		(2)	06/12/2036	Common Stock	87,900	$0	87,900	D

Explanation of Responses:

1. This transaction represents a grant of options pursuant to the terms of the Issuer's Amended and Restated Non-Employee Director Compensation Policy which provides for annual equity grants to the Issuer's non-employee directors on the date of the Issuer's Annual Meeting of Stockholders.

2. The shares subject to this option shall vest and become exercisable on the earlier of (i) June 12, 2027 or (ii) the date of the Issuer's 2027 Annual Meeting of Stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors.

	/s/ Cindy Tahl, as Attorney-in-Fact	06/15/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)